Cytosorbents Corporation
CTSOHealthcareNASDAQMedical Devices · Last scanned Sep 8, 2026
Scan Results
Daily timeframeCytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform in the United States, Germany, and. The $1.1M market capitalization puts CTSO squarely in micro-cap range for its industry. Its flagship product, CytoSorb, is an extracorporeal blood purification cartridge to reduce cytokine storms in common critical illnesses, bilirubin in liver failure, myoglobin in trauma and critical illnesses, and inflammatory mediators and blood thinners in cardiac surgery applications, as well as to remove antithrombotic drugs and inflammatory mediators in cardiothoracic surgery applications.
Market Cap
$1.1M
Beta
1.34
P/E (TTM)
—
P/E (Fwd)
—
EPS (TTM)
$-5.80
EPS (Fwd)
$0.00
ROE
-336.2%
ROA
-17.1%
Cash
$4.4M
Total Debt
$29.4M
Free CF
-$3.5M
52W Change
-64.4%
Annual Financials
Cash vs Debt
Where CTSO stands vs its 150-day and 200-day moving averages
As of the September 3, 2026 close, CTSO finished 26.92% below its 150-day moving average ($0.52) and 33.33% below its 200-day moving average ($0.57). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is CTSO overbought or oversold?
At the September 3, 2026 close, CTSO's RSI(14) was 53.9, in neutral territory (between 30 and 70). The MACD histogram was positive, so short-term momentum leaned bullish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
Cytosorbents Corporation carries $29.4M in total debt against $4.4M in cash reserves — debt is roughly 6.7x the cash position. Managing this leverage effectively will be important for long-term financial stability. Free cash flow is running at -$3.5M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. Return on equity stands at -336.2%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. Revenue has grown from $29.4M (2022) to $37.1M (2025), reflecting a 26% increase over the period.
The debt-to-cash ratio suggests meaningful leverage on the balance sheet, a factor worth monitoring if credit conditions tighten. The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. It is important to consider these factors alongside broader market conditions and individual financial goals when reviewing CTSO.